KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Total Non-Current Liabilities (2019 - 2025)

GoodRx Holdings' Total Non-Current Liabilities history spans 7 years, with the latest figure at -$625.0 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 195.18% year-over-year to -$625.0 million; the TTM value through Dec 2025 reached -$625.0 million, down 195.18%, while the annual FY2025 figure was -$625.0 million, 195.18% down from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was -$625.0 million at GoodRx Holdings, down from $717.2 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $818.9 million in Q3 2023 and bottomed at -$625.0 million in Q4 2025.
  • The 5-year median for Total Non-Current Liabilities is $764.5 million (2021), against an average of $681.3 million.
  • The largest YoY upside for Total Non-Current Liabilities was 10.41% in 2025 against a maximum downside of 195.18% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $770.6 million in 2021, then grew by 1.52% to $782.2 million in 2022, then increased by 4.66% to $818.7 million in 2023, then decreased by 19.79% to $656.7 million in 2024, then crashed by 195.18% to -$625.0 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Total Non-Current Liabilities are -$625.0 million (Q4 2025), $717.2 million (Q3 2025), and $668.6 million (Q2 2025).